
A close-up of hands holding a tablet and a pen

Description automatically generated**U.S. Liver Cancer Drug Market**

According to Intelli, the U.S. Liver Cancer Drug Market size was valued at USD 1,385.67 Million in 2024 and is projected to reach USD 4,756.34 Million by 2032, growing at a CAGR of 17.72% from 2025 to 2032.



Liver cancer, also known as hepatic cancer, is a life-threatening disease that arises when malignant cells form in the tissues of the liver. As one of the most vital organs in the body, responsible for detoxification, metabolism, and nutrient storage-the liver's impairment due to cancer can lead to rapid systemic decline. Globally, liver cancer ranks among the leading causes of cancer-related deaths, particularly in regions with high prevalence of chronic hepatitis B and C infections. The most common type of liver cancer is hepatocellular carcinoma (HCC), which originates in hepatocytes, the primary liver cells. Another, rarer form is intrahepatic cholangiocarcinoma, which affects the bile ducts. Liver cancer often presents few symptoms in its early stages, which contributes to late diagnosis and poor prognosis in many cases. Treatment of liver cancer has evolved significantly in recent decades, offering hope and improved survival rates for many patients. Therapeutic strategies depend on the cancer’s stage, the liver’s functionality, and overall patient health. Curative options include surgical resection (removal of the tumor) and liver transplantation, which can offer long-term survival in eligible patients. For those with unresectable tumors, locoregional therapies such as radiofrequency ablation (RFA), transarterial chemoembolization (TACE), and transarterial radioembolization (TARE) are commonly used to target cancer cells directly.

In advanced stages, systemic therapies play a critical role. These include targeted therapies like sorafenib and lenvatinib, and more recently, immunotherapy agents such as immune checkpoint inhibitors (e.g., atezolizumab in combination with bevacizumab), which have shown promising results in clinical trials. Ongoing research is also exploring combinations of immunotherapy, targeted agents, and traditional chemotherapy to enhance effectiveness.

**U.S. Liver Cancer Drug Market Definition**

The U.S. liver cancer drug market refers to the sector of the pharmaceutical and biotechnology industry that focuses on the research, development, production, marketing, and distribution of medications specifically used in the treatment of liver cancer within the A close-up of hands holding a tablet and a pen

Description automatically generatedUnited States. This market encompasses a wide range of therapeutic agents, including chemotherapy, targeted therapy, immunotherapy, and combination treatments designed to manage different stages and types of liver cancer. These key components ranging from cutting-edge biologics and emerging pipeline therapies to diverse distribution channels and advanced treatment settings, form the backbone of the U.S. liver cancer drug market, driving innovation, accessibility, and improved patient outcomes.

**U.S. Liver Cancer Drug Market Overview**

The U.S. liver cancer drug market is driven by several key factors that collectively support its growth and innovation. A primary driver is the increasing incidence and prevalence of liver cancer, largely fueled by rising cases of chronic hepatitis B and C, alcohol-related liver disease, and nonalcoholic steatohepatitis (NASH). Advancements in drug development, particularly in targeted therapies and immunotherapies, are expanding treatment options and improving patient outcomes. Strong research and development investments by major pharmaceutical and biotech companies, supported by favorable regulatory frameworks and fast-track approvals from the FDA, are accelerating the launch of novel therapies. Moreover, rising public awareness and the implementation of early screening programs are leading to earlier detection of liver cancer, significantly improving the chances of successful treatment. Enhanced healthcare infrastructure, marked by the proliferation of specialized oncology centers and academic medical institutions combined with increased healthcare expenditure and broader insurance coverage, is further expanding patient access to cutting-edge therapies.

**U.S. Liver Cancer Drug Market Segmentation**

The U.S. liver cancer drug market can be segmented across multiple dimensions to better understand its structure and growth dynamics.

**U.S. Liver Cancer Drug Market, By Drug Type**

* **Targeted Therapy Drugs**
* **Immunotherapy Drugs**
* A close-up of hands holding a tablet and a pen

  Description automatically generated**Chemotherapy Drugs**
* **Others**

In the U.S. liver cancer drug market, targeted therapy drugs dominate the landscape, holding the largest market share due to their proven efficacy and established use in first-line treatment, particularly agents like Sorafenib and Lenvatinib. Immunotherapy drugs are rapidly gaining traction, supported by the FDA approval of combination regimens such as Atezolizumab with Bevacizumab, which are demonstrating superior survival benefits. This segment is projected to witness the fastest growth rate in the coming years, driven by ongoing clinical trials and expanding indications. Meanwhile, the chemotherapy segment holds a declining share, primarily used in palliative care or when other options are unsuitable. The ‘others’ category, including investigational drugs and combination therapies, remains small but represents a dynamic pipeline with high growth potential.

**U.S. Liver Cancer Drug Market, By Cancer Type**

* **Hepatocellular Carcinoma**
* **Intrahepatic Cholangiocarcinoma**

In the U.S. liver cancer drug market, hepatocellular carcinoma accounts for the majority of the market share, as it represents approximately 70–85% of all primary liver cancer cases. In contrast, intrahepatic cholangiocarcinoma, a rarer and more aggressive form of liver cancer originating in the bile ducts, holds a smaller but growing market segment. Increased awareness, improved diagnostic capabilities, and emerging targeted therapies for intrahepatic cholangiocarcinoma such as FGFR inhibitors, are beginning to reshape treatment paradigms and attract pharmaceutical interest.

**U.S. Liver Cancer Drug Market, By Route of Administration**

* **Oral**
* **Intravenous**

In the U.S. liver cancer drug market, oral administration holds a significant share, primarily driven by the widespread use of targeted therapies. Oral drugs are especially preferred for long-term management of advanced hepatocellular carcinoma, contributing to their A close-up of hands holding a tablet and a pen

Description automatically generateddominance in this segment. On the other hand, the intravenous route is gaining rapid momentum, largely due to the growing adoption of immunotherapy regimens that require administration in clinical or hospital environments. The IV segment is expected to expand at a notable growth rate, supported by the increasing number of infusion-based therapies entering the market and the infrastructure readiness of oncology centers across the U.S.

**U.S. Liver Cancer Drug Market, By End User**

* **Hospitals & Clinics**
* **Cancer Research Institutes & Academic Medical Centers**
* **Homecare Settings**

In the U.S. liver cancer drug market, hospitals and clinics dominate as the primary end users, accounting for the largest market share. These settings are central to the administration of intravenous therapies, advanced treatments, and inpatient care for liver cancer patients, particularly in cases of advanced or metastatic disease. Cancer research institutes and academic medical centers are also significant players in the market, contributing to the development of cutting-edge treatments through clinical trials and research-based applications. Homecare settings are emerging as a growing segment due to the increasing availability of oral medications, which allow patients to manage their condition from the comfort of their homes. This shift towards homecare is fueled by both the convenience of oral therapies and the growing preference for less invasive, outpatient treatment options, offering a more patient-centric approach.

**Key Players**

The “U.S. liver cancer drug market" study report will provide valuable insight emphasizing the U.S. market. The major players in the market AbbVie, Bristol-Myers Squibb, Gilead Sciences, Merck & Co., Eli Lilly and Co., Regeneron Pharmaceuticals, Amgen, Johnson & Johnson, Pfizer, Biogen, AstraZeneca, Novartis, Boehringer Ingelheim Pharmaceuticals, Medtronic, Eisai Inc., Verrica Pharmaceuticals, Sanofi S.A., Thermo Fisher Scientific, Inc., Exelixis, Inc., Cadila Pharmaceuticals Ltd. among others. Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight A close-up of hands holding a tablet and a pen

Description automatically generatedinto the financial statements of all the major players, along with product benchmarking and SWOT analysis.

**Key Developments**

* In 2025, Rznomics Inc. achieved a major milestone as its anticancer drug RZ-001 received a second FDA Fast Track designation for the treatment of hepatocellular carcinoma, highlighting its potential as a promising new therapy for liver cancer.
* In 2025, Tempest Therapeutics received FDA Fast Track designation for its oral drug targeting PPARα, used in combination with atezolizumab and bevacizumab as a first-line treatment for unresectable liver cancer.
* In 2024, Bristol Myers Squibb received FDA acceptance for a new application to use nivolumab and ipilimumab combination as a first-line treatment for HCC.

**Market Attractiveness**

The image of market attractiveness provided further helps to get information about the region leading in the U.S. liver cancer drug market. We cover the major impacting factors driving the industry growth in the given region.

**Porter’s Five Forces**

The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be used to assess the competitive landscape U.S. liver cancer drug market, gauge the attractiveness of a particular sector, and assess investment possibilities.

A close-up of hands holding a tablet and a pen

Description automatically generatedTABLE OF CONTENT

1 **INTRODUCTION OF** **U.S. LIVER CANCER DRUG MARKET**

* 1. Overview of the market
  2. Scope of report
  3. Assumptions

1. **EXECUTIVE SUMMARY**
2. **RESEARCH METHODOLOGY**
   1. Data Mining
   2. Validation
   3. Primary Interviews
   4. List of Data sources
3. **U.S. LIVER CANCER DRUG MARKET OUTLOOK**
   1. Overview
   2. Market Dynamics
      1. Drivers
      2. Restrains
      3. Opportunities
      4. Trends
   3. Portes Five FORCE Model
   4. Value Chain Analysis

**5 U.S. LIVER CANCER DRUG MARKET, BY DRUG TYPE**

5.1 Overview

A close-up of hands holding a tablet and a pen

Description automatically generated5.2 Targeted Therapy Drugs

5.3 Immunotherapy Drugs

5.4 Chemotherapy Drugs

5.5 Others

**6 U.S. LIVER CANCER DRUG MARKET, BY CANCER TYPE**

6.1 Overview

6.2 Hepatocellular Carcinoma

6.3 Intrahepatic Cholangiocarcinoma

**7** **U.S. LIVER CANCER DRUG MARKET, BY ROUTE OF ADMINISTRATION**

7.1 Overview

7.2 Oral

7.3 Intravenous

1. **U.S. LIVER CANCER DRUG MARKET, BY END USER**
   1. Overview
   2. Hospitals & Clinics
   3. Cancer Research Institutes & Academic Medical Centers
   4. Homecare Settings
2. **U.S. LIVER CANCER DRUG MARKET COMPETITIVE LANDSCAPE**
   1. Overview
   2. A close-up of hands holding a tablet and a pen

      Description automatically generated Company Market Ranking
   3. Key Developments Strategies
3. **COMPANY PROFILES**

**10.1 AbbVie**

* + 1. Overview
    2. Financial Performance
    3. roduct Outlook
    4. Key developments
  1. **Bristol-Myers Squibb**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  2. **Gilead Sciences**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  3. **Merck & Co., Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  4. **Eli Lilly and Co.**
     1. A close-up of hands holding a tablet and a pen

        Description automatically generatedOverview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  5. **Regeneron Pharmaceuticals**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  6. **Amgen Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  7. **Johnson & Johnson**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments

* 1. **Pfizer**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  2. **Biogen**
     1. A close-up of hands holding a tablet and a pen

        Description automatically generatedOverview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  3. **AstraZeneca**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  4. **Novartis**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  5. **Boehringer Ingelheim Pharmaceuticals**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  6. **Medtronic**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  7. **Eisai Inc.**
     1. Overview
     2. A close-up of hands holding a tablet and a pen

        Description automatically generatedFinancial Performance
     3. Product Outlook
     4. Key developments
  8. **Verrica Pharmaceuticals**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  9. **Sanofi S.A.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  10. **Thermo Fisher Scientific, Inc.**
      1. Overview
      2. Financial Performance
      3. Product Outlook
      4. Key developments
  11. **Exelixis, Inc.**
      1. Overview
      2. Financial Performance
      3. Product Outlook
      4. Key developments
  12. **Cadila Pharmaceuticals Ltd.**
      1. Overview
      2. Financial Performance
      3. A close-up of hands holding a tablet and a pen

         Description automatically generatedProduct Outlook
      4. Key developments

1. **KEY DEVELOPMENTS**
   1. Product Launches/Developments
   2. Merges and Acquisitions
   3. Business Expansions
   4. Partnerships and Collaborations
2. **Appendix**

12.1 Related Research